by Fred Dumais | Sep 3, 2024 | News Release
MONTREAL, QUEBEC, September 3, 2024 – Valeo Pharma Inc. (TSX: VPH, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has entered into an agreement (the “Amendment”) with Sagard Healthcare Royalty Partners, LP...
by Fred Dumais | Aug 29, 2024 | News Release
MONTREAL, QUEBEC, August 29, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that the Company is voluntarily delisting its Class A shares from trading on the OTCQB Venture...
by Fred Dumais | Aug 6, 2024 | News Release
MONTREAL, QUEBEC, August 6, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that the Company’s Chief Development Officer, Mr. Al Moghaddam, has been appointed to succeed...
by Fred Dumais | Jun 18, 2024 | News Release
MONTREAL, QUEBEC, June 18, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that Mr. Al Moghaddam has been appointed to the newly created role of Chief Development Officer...
by Fred Dumais | Jun 13, 2024 | News Release
Record Q2-24 revenues of $14.1 million, up 4% over Q2-23 outpacing revenue softness in several non-core brands Q2-24 adjusted EBITDA loss of $2.5 million compared to $1.7 million for Q2-23, up 48% Total Enerzair and Atectura prescriptions for the 12 months...
by Fred Dumais | Jun 13, 2024 | News Release
Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exceeding $2 million Restructuring charges to be incurred in Q3-24 Cost reduction initiatives are aimed at improving margins,...
